As summarized in [10] in patients with T2DM and obesity the acute effect of 11beta-HSD1 inhibition is most likely improvement of glucose metabolism by reduction of glucocorticoid-mediated hepatic glucose output. Here, HSD11B1 is linked to obesity due to melanocortin 4 receptor deficiency.